

**ASX / Media Release**

**10 March 2011**

---

## **RHT: Resonance Health Expands its Master Service Agreement for Liver Iron Test**

Resonance Health Limited (RHT) has signed an Addendum to the Master Service Agreement with Novartis to provide FerriScan<sup>®</sup> R2-MRI services to Novartis worldwide for non-clinical trial purposes.

FerriScan<sup>®</sup> R2-MRI is an accurate, non-invasive MRI-based test for diagnosing and monitoring iron overload and is extremely important for individuals with, or suspected of having, systemic iron overload where a definitive diagnosis of iron overload is required. It is also a valuable tool for monitoring liver iron burden as part of ongoing clinical management of patients. FerriScan<sup>®</sup> R2-MRI has been used by Novartis since 2004 as part of a clinical development program for their iron chelation product, which is currently approved in more than 100 countries for transfusional iron overload. A new Master Service Agreement was signed with Novartis in October 2010 for the continued provision of FerriScan<sup>®</sup> R2-MRI services for their clinical trial programs.

This Addendum to the Master Service Agreement establishes an agreed framework for Novartis to use FerriScan<sup>®</sup> R2-MRI in its non-clinical trial programs.

This announcement represents a significant opportunity for Resonance Health to continue its close collaboration with Novartis.

By Order of the Board  
Resonance Health Limited

For further information please contact:

**Resonance Health**

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Colin McDonald  
Company Secretary  
T: +61 8 9286 5300  
E: [colinm@ferriscan.com](mailto:colinm@ferriscan.com)

---

### **About Resonance Health Ltd**

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company developing innovative imaging technology for the assessment of human disease. The Company's expertise is in providing quantitative measurements using MRI technology replacing the need for invasive procedures such as a biopsy. Its lead product on market is FerriScan<sup>®</sup>, for the measurement of iron overload using a unique and patent protected R2-MRI methodology. Pipeline products include imaging products for the measurement of liver fat and liver fibrosis. A recently agreed exclusive worldwide license for a product providing an imaging based measurement of amyloidosis and fibrosis provides an expanding portfolio of products for the Company.